Besides the 3-month-duration broadly effective antiviral prophylactics that Josh mentioned, I think that daily broadly antiviral prophylactics could also be promising if they could eventually become widespread consumer products. However, the science is still pretty nascent – at least for prophylaxis, I don’t believe there is much human data at all, and I haven’t seen anything I’ve seen reaches truly 24 h duration efficacy (which I’d see as a major barrier to consumer uptake).
I think transmission reduction hasn’t been tested specifically, but anything that’s localized to the upper respiratory tract and is prophylactic should theoretically reduce transmission as well.
Besides the 3-month-duration broadly effective antiviral prophylactics that Josh mentioned, I think that daily broadly antiviral prophylactics could also be promising if they could eventually become widespread consumer products. However, the science is still pretty nascent – at least for prophylaxis, I don’t believe there is much human data at all, and I haven’t seen anything I’ve seen reaches truly 24 h duration efficacy (which I’d see as a major barrier to consumer uptake).
Here are some links:
“PCANS”, and its commercial product Profi nasal spray
INNA-051 ferret study, Phase 2 influenza challenge study (press release and more negative take)
“SHIELD”
I think transmission reduction hasn’t been tested specifically, but anything that’s localized to the upper respiratory tract and is prophylactic should theoretically reduce transmission as well.